Qiagen N.V. (NYSE:QGEN) Holdings Decreased by US Bancorp DE

US Bancorp DE trimmed its holdings in Qiagen N.V. (NYSE:QGEN - Free Report) by 18.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 57,357 shares of the company's stock after selling 13,243 shares during the period. US Bancorp DE's holdings in Qiagen were worth $2,303,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd acquired a new position in shares of Qiagen in the 1st quarter valued at about $94,000. Tower Research Capital LLC TRC lifted its stake in shares of Qiagen by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Qiagen by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares in the last quarter. Federated Hermes Inc. acquired a new position in shares of Qiagen in the 1st quarter valued at about $150,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Qiagen in the 4th quarter valued at about $202,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Down 0.7%

QGEN stock traded down $0.34 during midday trading on Friday, hitting $48.02. 1,293,968 shares of the company's stock were exchanged, compared to its average volume of 1,692,426. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The firm has a 50 day moving average price of $48.02 and a 200-day moving average price of $43.55. The stock has a market capitalization of $10.67 billion, a price-to-earnings ratio of 28.37, a price-to-earnings-growth ratio of 2.45 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%. The company had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the previous year, the business earned $0.55 EPS. Qiagen's revenue for the quarter was up 7.7% compared to the same quarter last year. On average, analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Dividend Announcement

The company also recently declared a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were issued a $0.25 dividend. This represents a dividend yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen's payout ratio is 14.79%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on QGEN shares. UBS Group lifted their price objective on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday. Barclays started coverage on Qiagen in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Wall Street Zen upgraded Qiagen from a "buy" rating to a "strong-buy" rating in a report on Sunday, August 3rd. Finally, Robert W. Baird raised their target price on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Eight analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.